Key facts
- It has raised $7.3M.
- Notable investors include Flybridge (New York), University of Toronto Entrepreneurship, Company Ventures, XFactor Ventures, MBX Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Juniper Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Juniper Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Juniper Genomics
Operator of a genomics and data science company intended to help parents make informed decisions about themselves and their embryos. The company's technology uses modern genomics and data science to help overcome the barriers and challenges facing IVF patients and offer a chance at term pregnancy, enabling future parents to understand and use data from themselves and their embryos to make decisions that are right for their families.
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2020
- Employees
- 9
- Website
- junipergenomics.com/
- Ownership
- Privately Held (backing)
Juniper Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Juniper Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Juniper Genomics in its N-PORT filings yet. We sweep new filings monthly.